Karl Dahlquist Sells 9,370 Shares of AtriCure (NASDAQ:ATRC) Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Karl Dahlquist sold 9,370 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. This trade represents a 9.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

AtriCure Stock Up 2.3%

Shares of ATRC stock opened at $49.27 on Friday. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of 234.63 and a beta of 1.20. AtriCure, Inc. has a one year low of $25.36 and a one year high of $49.88. The company’s fifty day moving average price is $37.50 and its 200-day moving average price is $32.14. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter in the prior year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Sell-side analysts expect that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in AtriCure by 13.7% during the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company’s stock valued at $21,927,000 after buying an additional 92,830 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of AtriCure during the 2nd quarter worth approximately $1,744,000. Rice Hall James & Associates LLC bought a new position in shares of AtriCure during the 2nd quarter valued at approximately $3,755,000. F m Investments LLC bought a new position in shares of AtriCure during the 4th quarter valued at approximately $2,872,000. Finally, Vanguard Group Inc. grew its holdings in shares of AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company’s stock valued at $193,993,000 after purchasing an additional 62,861 shares in the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ATRC shares. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings upgraded AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Finally, BTIG Research increased their price objective on shares of AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.89.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.